34 results about "Embolic Agent" patented technology

A system for transvascular delivery to an aortic arch of a patient includes an embolic protection device, a connector mechanism, and a catheter or sheath for delivering the embolic protection device to a working zone. The embolic protection device includes a support frame having a distal portion and a proximal portion, and a filter member attached to the support frame and configured for preventing embolic materials from passing there through. At least one of the distal portion and the proximal portion includes a spring section configured for providing a radial force between the support frame and a wall of the aortic arch when in an expanded state. The embolic protection device is pivotable axially but not radially relative to the connector mechanism.

This application provides a premix, kit, and application of a premix for preparing an embolic agent. The premix uses a poloxamer to sodium alginate mass ratio of 9:1 to 20:1, which enables the formation of an injectable solution while maintaining good gel properties, and offers ease of preparation and use.

The invention provides a premixing agent for preparing an embolic agent, a kit and application of the premixing agent. The premix adopts poloxamer and sodium alginate in a mass ratio of 9: 1-20: 1, can form a solution with good injectability in use, keeps good gel performance, and is good in preparation and use convenience.

The invention provides a developing agent which is modified iopamidol, a clinically safe nonionic hydrophilic developing agent iopamidol is subjected to structural modification, a hydrophilic side chain and a connecting arm are introduced, and the iopamidol is introduced into a gelatin degradable microsphere matrix with good biocompatibility in a covalent bonding manner; the degradable non-ionic X-ray developing microsphere with good biocompatibility is formed. Developing microspheres prepared by adopting the developing agent provided by the invention not only keep excellent X-ray developing performance, solve the problems of aggregation tendency and biocompatibility of traditional developing microspheres and realize real-time visual monitoring of an embolism process, but also have degradability and good biological safety, and are not only suitable for permanent embolism treatment, but also suitable for treatment of embolism. The solid developing embolism agent can also be expanded to the fields of temporary embolism, tissue engineering and the like, and the solid developing embolism agent with precise developing and safe degradation performance is provided for minimally invasive interventional therapy of diseases such as tumor intervention and vascular malformation.

The application relates to a composite nanogel and a preparation method and application thereof, in particular to the technical field of biomedical materials. The composite nanogel comprises a nanogel framework and tirapazamine and folic acid loaded on the nanogel framework, wherein raw material components of the nanogel framework comprise a temperature-sensitive monomer and a monomer containing a catechol group. The composite nanogel provided by the application can solve the problems that poor blood vessel adhesion of traditional embolic agents easily leads to embolism recanalization, simple physical embolism is difficult to completely remove hypoxic tumor cells, and existing treatment strategies cannot effectively reverse the immune suppression microenvironment after embolism and activate the systemic anti-tumor immune response.

A detachable tip sheathed balloon microcatheter is provided for delivering an embolic agent to a target location for the embolization of an arteriovenous malformation (AVM). The detachable tip sheathed balloon microcatheter including a balloon microcatheter including a first shaft and an inflatable balloon that is coupled to a distal end portion of the first shaft; and a detachable tip assembly that is configured to be detachably coupled to the first shaft of the balloon microcatheter. The detachable tip assembly includes a protective balloon sheath that is coupled to a proximal end portion of the second shaft, wherein when the detachable tip assembly is coupled to the balloon microcatheter, the protective balloon sheath surrounds at least a portion of the inflatable balloon.

A nanocarbon-iodine calcium alginate microspheres and a preparation method thereof are provided, the nanocarbon is added to the microspheres to enhance an imaging capability of iodine under X-ray, which is a good way to solve a problem that an embolic agent in clinical application cannot be imaged under X-ray. In addition, the preparation method is simple with good stability and safety. It is proved through experiments that the microspheres can be imaged under conventional interventional X-ray examination devices in CT and DSA, it is proved through animal experiments that the microspheres have good X-ray imaging performance and embolization effect.

The present invention discloses the use of a short-term embolic agent in reducing drug accumulation in the liver, hepatic clearance and / or liver toxicity. The present invention provides the use of a short-term embolic agent in the manufacture of a medical composition for: (a) temporarily embolizing blood vessels supplying the liver; and (b) reducing the accumulation of a drug subsequently or concurrently administered intravenously in the liver. The strategy aims to minimize the exposure of a drug (such as LNP) to the liver by temporarily blocking the blood supply to the liver via the portal vein and / or arteries. The present invention significantly reduces the non-specific accumulation of a drug in the liver by temporarily blocking the portal vein, arterial and / or their branch blood flow, thereby greatly reducing the opportunity for the drug to enter the liver from a hemodynamic root.

The invention relates to composite nanogel as well as a preparation method and application thereof, in particular to the technical field of biomedical materials. The composite nanogel comprises a nanogel skeleton, tirapazamine and folic acid, the tirapazamine and the folic acid are loaded on the nanogel skeleton, and raw material components of the nanogel skeleton comprise a temperature-sensitive monomer and a monomer containing a catechol group. The composite nanogel provided by the invention can solve the problems that a traditional embolism agent is poor in blood vessel adhesion and easy to cause embolism recovery, hypoxia tumor cells are difficult to thoroughly remove by pure physical embolism, and an immunosuppressive microenvironment after embolism cannot be effectively reversed and systemic anti-tumor immune response cannot be activated by an existing treatment strategy.

[0003] A light-transmitting microcatheter device and method for intravascular embolization are described herein. A microcatheter device is provided, comprising a working lumen and a mechanically protected waveguide. The working lumen has at least one exit port at a distal end of the working lumen and is configured for intravascular injection of a photoactivated embolic agent (PEA) into a target vessel through the at least one exit port. A mechanically protected waveguide (MPW) is operably connected to the working lumen and configured to emit at least one electromagnetic wave through the at least one exit port for delivery to the target vessel.

A system or device for infusing a therapeutic agent to a blood vessel of a patient includes a catheter arrangement and a turbulence inducing structure. The catheter arrangement extends from a distal end to a proximal end, having an outer surface and an inner surface. The catheter arrangement includes an opening at a distal tip of the catheter arrangement in a continuous fluid passage having a lumen extending through the catheter arrangement defined by the inner surface. The turbulence inducing structure is formed by or attached to the outer surface of the catheter arrangement or the distal tip of the catheter arrangement. The turbulence inducing structure is configured to induce turbulence on blood flowing through a localized region of the blood vessel. The turbulence inducing structure is dimensioned and shaped appropriately to incompletely occlude the blood vessel such that the blood can flow through the turbulence inducing structure.

The invention discloses body temperature responsive self-adhesive gel microspheres as well as a preparation method and application thereof, and relates to the technical field of medicines. The body temperature responsive self-adhesive gel microspheres comprise a photocuring structure stabilizing unit material and a body temperature responsive self-adhesive unit material; the photocuring structure stable unit material comprises at least one of a natural polymer derivative material and a synthetic polymer material; the body temperature responsive self-adhesive unit material can be subjected to chain segment migration and re-entanglement at a physiological temperature. The gel microsphere has good temperature-controlled self-adhesion capability and interface adhesion property, and can be used as an embolism agent for treating vascular embolism.

Provided in the present application are the use of zein as an embolic agent, a zein embolization system and a zein-drug composite embolization system, and the use in the preparation of a drug for transcatheter arterial chemoembolization. The present application belongs to the technical field of medicine. In the present application, zein is used as an embolic agent in the preparation of a drug for transcatheter arterial chemoembolization, which has an excellent therapeutic effect. Specifically, in the present application, zein is used as an embolic agent to facilitate the starvation therapy of TACE. In addition, zein also has high tissue adhesion, so that a zein-based embolization system has a high mechanical strength, and can resist deformation caused by the blood pressure and detachment caused by blood flow flushing. In addition, in the present application, zein is used as an embolic agent to restrict the site of drug action and facilitate the extension of the therapeutic approaches of a drug in chemotherapy. On this basis, zein is integrated with TACE-supported starvation therapy, can be used for TACE treatment of liver cancer, and is beneficial to improving the therapeutic effect.

A nanocarbon-iodine calcium alginate microspheres and a preparation method thereof are provided, the nanocarbon is added to the microspheres to enhance an imaging capability of iodine under X-ray, which is a good way to solve a problem that an embolic agent in clinical application cannot be imaged under X-ray. In addition, the preparation method is simple with good stability and safety. It is proved through experiments that the microspheres can be imaged under conventional interventional X-ray examination devices in CT and DSA, it is proved through animal experiments that the microspheres have good X-ray imaging performance and embolization effect.

The invention discloses a developing plasticizer, a preparation method and a liquid embolism agent, and relates to the field of medical materials. According to the invention, citric acid, an epoxy compound and hydrogen iodide are taken as raw materials to synthesize the citric acid iodo-ester compound connected with the iodine atoms through covalent bonds, so that the iodine atoms are uniformly arranged on the molecules of the citric acid iodo-ester compound, and the dispersity of the iodine atoms when the iodine atoms are applied to the liquid embolism agent is improved. By adding the citric acid iodo-ester compound, the problems that in the prior art, after an additional developing agent needs to be added, the mixing compatibility of the developing agent and cyanoacrylate is poor, and the mechanical property of the cured cyanoacrylate is reduced are solved. When the developing plasticizer is applied to a liquid embolism agent, the liquid embolism agent has developing performance, and the embolism agent can be directly observed in the embolism process.

This invention belongs to the field of biomedical technology, specifically disclosing an injectable embolic agent, its preparation method, and its application. The embolic agent is a hydrocolloid system containing core-shell structured nanoparticles: the core contains Cu... 2+ Salt and ATOX1 inhibitors, where ATOX1 inhibitors can inhibit copper ion efflux and promote intracellular copper accumulation, and interact with Cu 2+ It synergistically induces copper death in tumor cells; the shell is a thermosensitive block copolymer hydrogel that can interact with Cu. 2+ Coordination bonds are formed, enhancing the stability of nanoparticles, while a sol-gel transition occurs at physiological temperatures, enabling precise vascular embolization; the overall core-shell structure allows for the formation of Cu... 2+ The sustained-release effect of ATOX1 inhibitors was observed. In the VX2 rabbit hepatocellular carcinoma model, this embolization agent significantly improved tumor necrosis rate and reduced metastasis rate compared to traditional iodized oil embolization; it also downregulated hypoxia- and angiogenesis-related factors such as HIF-1α, VEGF, and CD31, inhibited MMP9-mediated tumor invasion and metastasis, and promoted CD8+. + T-cell infiltration effectively improves the tumor immunosuppressive microenvironment after transarterial chemoembolization.

The invention provides a duplex injection and suction device. The duplex injection and suction device comprises a shell and an injection and suction driving assembly, the shell is provided with two installation structures arranged side by side, and the two installation structures are used for installing and maintaining a first injector and a second injector correspondingly; the injection and suction driving assembly is connected with the shell and used for driving the first injector and the second injector to conduct pushing injection and suction synchronously. One injector sucks blood to block blood flow in a blood vessel, and the other injector injects embolism substances into the blood vessel, so that the embolism substances are prevented from drifting along with the blood flow, the embolism substances accurately act on a target blood vessel area, operation can be completed with one hand, and the operation difficulty is reduced.

To provide a preparation for tumors and a method for preparing the same.SOLUTION: A tumor preparation, characterized in that the tumor preparation comprises active metal microspheres, wherein the active metal microspheres are prepared from an active metal, and the active metal has a metal activity stronger than that of hydrogen and is selected from at least one of magnesium, zinc, gallium, manganese and tin. Preferably, the active metal microsphere has a particle size of 0.1 to 500 microns.SELECTED DRAWING: None

The application provides a premix agent for preparing embolic agents, a kit and application thereof. The premix agent adopts a mass ratio of poloxamer and sodium alginate of 9:1-20:1, can form a solution with good injection in use, and maintains good gel performance, and has good preparation and use convenience.

The invention relates to a liquid embolism agent as well as a preparation method and application thereof. The liquid embolism agent contains 20-40 wt% of tantalum powder and 60-80 wt% of a continuous phase solution; the sum of the contents of the components of the liquid embolism agent is 100%; the continuous phase solution comprises EVOH and DMSO in a volume ratio of (1: 13)-(1: 23); the particle size distribution of the tantalum powder dispersed in the liquid embolism agent ranges from 500 nm to 5000 nm, and the particle size distribution Span value ranges from 1.5 to 2.0. By controlling the particle size of the tantalum powder, the particle size distribution Span value and the proportion of all the components, the tantalum powder forms a stable suspension state in the solution, the toughness of the cured embolism body is improved, and the fracture toughness of the embolism body in the deformation and pressure bearing process is enhanced.

The invention relates to the technical field of medical treatment, in particular to an embolic agent for slowly releasing triptolide with an open type porous structure. The embolization agent is triptolide-loaded perforated PBVHx microspheres, and the microspheres are marked as TP (at) OPMs; the TP (at) OPMs has a porous structure of which the surface is provided with pores and the internal pores are mutually communicated, PBVHx contains 90 mol% of 3-hydroxybutyric acid, 3 mol% of 3-hydroxyvaleric acid and 7 mol% of 3-hydroxyhexanoic acid, and the molecular weight is 46 kDa. According to the embolic agent for slowly releasing the triptolide with the open type porous structure provided by the invention, a novel non-lactic acid polymer PBVHx is used as a basis, and an improved double emulsion method (G / O / W) is adopted to prepare a novel triptolide (TP)-loaded open pore microsphere (TP-coated OPMs) which is used for chemoembolization treatment.

The invention discloses a double-load alkaline gelatin developing microsphere as well as a preparation method and application thereof, and belongs to the technical field of biomedical engineering. The method comprises the following steps: dispersing sodium bicarbonate nanoparticles and barium sulfate in a hot gelatin solution, extruding into drops through an injection pump, dropwise adding the drops into liquid paraffin which is stirred at a low temperature, freezing and forming, crosslinking and curing at a low temperature through a glutaraldehyde isobutanol solution, and washing and drying to obtain a final product. The double-loaded alkaline gelatin developing microspheres obtained by the invention are uniform in particle size (300-500 [mu] m) and good in dispersity, barium sulfate endows the double-loaded alkaline gelatin developing microspheres with stable and lasting X-ray developing capacity, and the entrapped sodium bicarbonate nanoparticles can slowly release alkaline substances, effectively neutralize lactic acid in a tumor microenvironment and reverse chemotherapy drug resistance caused by the alkaline substances. The microsphere provided by the invention is simple and controllable in preparation process, can be used as an embolic agent with developing guiding and drug resistance reversing functions, and is used for tumor interventional therapy.

The invention relates to a system based on the anatomy of the middle meningeal artery, for simulating embolisation with embolic substances. The configuration of the system allows for quick assembly and disassembly, facilitating its use in training workshops. This improves the quality of medical training and promotes the use of this non-invasive treatment for chronic subdural haematomas. The invention comprises a base that acts as a support and stabiliser, and a branched model which, with internal diameters of up to 0.5 mm, replicates the actual internal anatomical tortuosity of the middle meningeal artery.

Disclosed in the present invention are a nano-carbon–iodine calcium alginate microsphere and a preparation method therefor. In the microsphere, the development capability of iodine under X-ray is enhanced by means of adding nano-carbon, and thus the microsphere provides a good approach for solving the problem whereby an embolic agent cannot be developed under X-ray in clinical application. The microsphere has a simple preparation method and has good stability and safety. Experiments confirm that the microsphere can be developed under conventional interventional X-ray examination equipment, such as CT and DSA; and animal experiments confirm that the microsphere has good X-ray developing performance and a good embolization effect.

The invention provides a premixing agent for preparing an embolic agent, a kit and application of the premixing agent. The premix adopts poloxamer and sodium alginate in a mass ratio of 9: 1-20: 1, can form a solution with good injectability in use, keeps good gel performance, and is good in preparation and use convenience.

The invention discloses a high-developability and dispersivity liquid embolism agent and application thereof, and belongs to the technical field of medical instruments. The iodinated polymer and PEG-I are compounded, so that the overall iodine content of the liquid embolization agent is increased, and the visibility in an operation is enhanced. Meanwhile, the PEG block polymer and the PEG-I have good compatibility, and the entanglement effect between macromolecular chains can be greatly weakened by adding the liquid PEG-I, so that the overall rheological property of the mixture is enhanced, a macroscopically uniform mixture can be formed, and the dispersion uniformity of the embolization agent in a vascular bed is improved.

A detachable tip sheathed balloon microcatheter is provided for delivering an embolic agent to a target location for the embolization of an arteriovenous malformation (AVM). The detachable tip sheathed balloon microcatheter including a balloon microcatheter including a first shaft and an inflatable balloon that is coupled to a distal end portion of the first shaft; and a detachable tip assembly that is configured to be detachably coupled to the first shaft of the balloon microcatheter. The detachable tip assembly includes a protective balloon sheath that is coupled to a proximal end portion of the second shaft, wherein when the detachable tip assembly is coupled to the balloon microcatheter, the protective balloon sheath surrounds at least a portion of the inflatable balloon.

An embolization member (10) and a method for fabricating it are disclosed. The embolization member (10) includes a tubular first helical member (100) comprising a lumen (110), a second helical member (120) sleeved over an outer surface of the first helical member (100) and a securing member (170) at least partially disposed within the lumen (110) of the first helical member (100). The first helical member (100) includes a radiopaque material, and the second helical member (120) includes a bioabsorbable material. The securing member (170) is coupled at opposite ends thereof to respective opposite ends of the second helical member (120), so as to secure the first helical member (100) to the second helical member (120). The securing member (170) incorporated in the double-layer structure of the embolization member (10) not only imparts degradability to the embolization member (10), which can mitigate a possible mass effect that it may exert, but also enable it to maintain good structural stability within an aneurysm.